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ScienceDirectTransdifferentiation of one cell type to another has
garnered significant research efforts in recent years. As
cardiomyocyte loss following myocardial infarction becomes
debilitating for cardiac patients, the option of an autologous
source of cardiomyocytes not derived from multi/pluripotent
stem cell sources is an attractive option. Such direct
programming has been clearly realized with the use of
transcription factors, microRNAs and more recently
small molecule delivery to enhance epigenetic modifications,
all albeit with low efficiencies in vitro. In this review, we aim
to present a brief overview of the current in vitro and
in vivo transdifferentiation strategies in the generation
of cardiomyocytes from somatic sources. The
interdisciplinary fields of tissue, cell, material and
regenerative engineering offer many opportunities to
synergistically achieve directly programmed cardiac tissue in
vitro and enhance transdifferentiation in vivo. This review
aims to present a concise outlook on this topic with these
fields in mind.
Addresses
1Department of Women’s Health, Research Institute for Women’s
Health, Eberhard Karls University, Tu¨bingen, Germany
2Department of Cell and Tissue Engineering, Fraunhofer Institute for
Interfacial Engineering and Biotechnology (IGB), Stuttgart, Germany
3Department of Medicine/Cardiology, Cardiovascular Research
Laboratories, University of California, Los Angeles, CA, USA
Corresponding author: Schenke-Layland, Katja
(katja.schenke-layland@med.uni-tuebingen.de)
Current Opinion in Biotechnology 2016, 40:49–55
This review comes from a themed issue on Tissue, cell and pathway
engineering
Edited by April Kloxin and Kyongbum Lee
For a complete overview see the Issue and the Editorial
Available online 3rd March 2016
http://dx.doi.org/10.1016/j.copbio.2016.02.014
0958-1669/# 2016 The Authors. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/4.0/).
Introduction
Cardiovascular disease is one of the world’s leading
causes of mortality. Myocardial infarction (MI) is the
death of heart tissue due to ischaemia, typically caused
by the blockage of blood flow to an area in the heart.
Resident cardiomyocytes have a very limited capacity towww.sciencedirect.com proliferate in the adult heart, resulting in the lack of heart
regeneration post-MI [1]. To date, the most efficient
therapy for heart failure is whole organ transplantation,
which is limited by donor hearts availability, compro-
mised by immunosuppressant therapy and an invasive
procedure not suitable for all patients.
Cell therapies have been of interest to researchers due to
their variety of cell sources, the ability to scale-up in vitro
and their potential to improve the regeneration of tissue.
This has evolved from research with autologous stem cell
sources — bone marrow-derived stem cells, adipose
tissue-derived stem and progenitor cells, all of which
have reached clinical trials [2]. Recent approaches to
induce a pluripotent state in various adult somatic cells,
termed induced-pluripotent stem cells (iPSCs), has
resulted in exciting work towards clinical therapy and
disease modelling [3]; however, returning cells to a
pluripotent state raises concerns of teratoma formation
and possible unwarranted differentiation [4]. Prompted
by the advent of iPSCs [3], the concept of a direct
transition from one determined cell type into another
(transdifferentiation) by overexpressing transcription
factors, microRNAs (miRs) and/or delivering small mole-
cules has emerged [5,6,7]. Almost 30 years ago,
myogenic features in fibroblasts were being driven by
introducing the expression of the muscle-specific tran-
scription factor MyoD [8]. This direct conversion was
achieved by epigenetic suppression  of the fibroblast
phenotype and progressive activation of the target cell
via cDNA transfections. Transdifferentiation has since
been reported for cell types such as pancreatic beta cells
[9], neurons [10], hepatocyte-like cells [11], and haema-
topoietic progenitor cells [12]. Inducing functional car-
diomyocytes (iCMs) directly from fibroblasts was first
reported with murine cells in 2010 [5]. Since then,
substantial efforts have been applied to increase trans-
differentiation efficiencies [13]. Gradually, the incor-
poration of additional stimuli such as dynamic cultures,
mechanical, topographical and extracellular matrix
(ECM) cues, along with other lessons learned from stem
cell and iPSC differentiation is slowly impacting the
direct reprogramming protocols with increased efficien-
cies. In this review, we aim to discuss the important
developments in the transdifferentiation of fibroblasts
to iCMs in vitro and in vivo with the goal of highlighting
developments in the field of tissue engineering and
biomaterials design that could realize exciting accom-
plishments in this field.Current Opinion in Biotechnology 2016, 40:49–55
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transcription factors
Typically, cardiac fibroblasts maintain the structural and
paracrine sustenance of adjacent cardiomyocytes. How-
ever, activation of these fibroblasts occurs after MI and
subsequently they migrate to the site of injury and
synthesize fibrotic ECM as a compensatory structure
for the compromised myocardium [1]. The abundance
of cardiac fibroblasts in the injured heart intuitively high-
lights them as a target for reprogramming, whereby they
could offer as a source for cardiac regeneration. Cardiac
fibroblasts and cardiomyocytes, in theory, should share
many epigenetic features as they both derive from a
common progenitor cell population [14]. The significance
of the originating cell type and its natural environment
has been reported in myogenic [15] and pancreatic beta
cell reprogramming [9]. In both cases, somatic cells
originating from different germ layers to that of the
envisaged cell type failed to yield successful transdiffer-
entiation.
The most documented and the first factors to derive iCMs
are the transcription factors Gata4, Mef2c and Tbx5
(GMT). Since their initial reporting [5], many repro-
gramming cocktails have been tested, most of them
virally delivered and based on the original combination
of GMT but with additional factors (Mesp1, Hand1,
Hand2, Nkx2.5, myocardin (Myocd), Smarcd3 or SRF)
to improve reprogramming efficiencies [16,17–19] (see
Table 1 for an overview). G, M, and T are the prevailing
regulators at the peak of the cardiac gene regulatory
networks and their expression during normal develop-
ment follows a delicate pattern [20]. It is reported that
GMT alone is inefficient to produce functional iCMs but
results in a partially reprogrammed phenotype expressing
transcripts such as cardiac TroponinT but not alpha
myosin heavy chain (a-MHC) [21]. Combining Myocd
with Tbx5 and Mef2c to treat neonatal cardiac fibroblasts
has resulted in a 2.5% yield of a-MHC-expressing cells
14 days post-transduction (GMT alone achieved 2.2%);
however, complete transdifferentiation in the form of
beating cells after four weeks was not obtained [22].
It is also reported that a fine balance of the GMT factors is
required to accomplish more efficient transdifferentiation
[20,23]. Essentially, a high Mef2c protein level and lower
expression level of Gata4 and Tbx5 transpired to be key in
yielding iCMs in fibroblasts transduced by a polycistronic
vector [20]. Stoichiometry of the factors has also been
found to have an effect through non-viral mRNA delivery
[23]. Such a sensitive equilibrium may be one reason why
GMT has yielded poor efficiency in other researchers’
investigations. Repression of Snai1 has been implicated
as an enhancer of GMT transdifferentiation as Snai1 is
capable of inducing mesenchymal behaviour and fibrogen-
esis during development and disease. Knocking down
Snai1-expression with siRNA during GMT transductionCurrent Opinion in Biotechnology 2016, 40:49–55 of MEFs significantly increased the reprogramming effi-
ciency compared to GMT alone [24]. In contrast, over-
expressing Snai1 during transdifferentiation inhibited
cardiac gene expression and spontaneous beating. Other
researchers have noted a fivefold improvement of iCM
induction has been achieved via inhibition of TGF-b using
SB431542 with transfection of GMT + Hand2 + Nkx2.5
[25]. TGF-b acts as an activator of Snai1. Therefore both
studies establish that the repression of Snai1 is important to
stop the maintenance of the fibroblast phenotype. Addi-
tionally, a more recent study found that although GMT and
Hand2 transdifferentiated fibroblasts into beating cells
expressing cardiac markers (5%), genes associated with
fibrosis were also upregulated in the first week of culture
[26]. On the basis of the hypothesis that fibrotic signalling
was hindering transdifferentiation, small molecules to si-
lence TGF-b and Rho associated kinase signalling yielded
an efficiency of 60% functional cardiomyocytes from
mouse embryonic fibroblasts [26].
microRNA mediated transdifferentiation
The role of miRs and the disruption of their endogenous
levels and cell-specific functions following MI are well
reported [27]. The regulatory role of miRs in the sup-
pression of mRNA translation plays an important role in
cell fate decisions, which can have a knock-on/off effect
on the presence of transcription factors and other stimu-
latory factors. Jayawardena et al. were the first who iden-
tified a cocktail of miRs (miR-1, -133, -208, -499) that
seemed to preferably transdifferentiate fibroblasts into
iCMs [6]. Within this study; cardiac protein expression,
rhythmic calcium oscillations and beating clusters were
observed in about 1–2% of the cell population [6].
Notably, the introductory method of the miRs in this
study (non-viral delivery of mature miR mimics) necessi-
tated a single transient transfection.
Muraoka et al. investigated the effect of miR-1, -133,-208,
and -499 on mouse embryonic fibroblasts (MEFs) isolated
from a-MHC promoter-driven eGFP transgenic mice in
generating iCMs [24]. This study was not successful in
generating iCMs using this defined cocktail of miRs.
However, combining GMT viral delivery with just
miR-133 (non-viral mature miR mimic) resulted in sig-
nificantly enhanced transdifferentiation efficiencies in
murine and human fibroblasts [24]. When investigating
the cardiomyocyte subtype they observed mostly iCMs of
an atrial phenotype. Interestingly, the study detected
beating events in GMT+ miR-133 transduced MEFs as
early as day 10 post-induction; whereas cells treated with
GMT alone did not exhibit beating cells until four weeks
post-induction.
Another approach in converting fibroblasts to iCMs is the
combination of transiently overexpressing factors gener-
ally recognized for iPSC generation, with culture condi-
tions and factors specific to cardiac differentiation, butwww.sciencedirect.com
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duced MEFs with Oct4, Sox2, Klf4 (OSK) and cultured
under defined conditions (LIF-free cardiomyogenic me-
dia) using small molecules and growth factors [28] and
induced spontaneously contracting patches of cardiac
cells. This study found that small molecule inhibition
of JAK-STAT (Janus kinase-signal transducer and activa-
tor of transcription) during the initial nine day period and
supplementation of BMP4 from day nine gave more
beating cells. However, regardless of the culture time,
the expression of late stage markers (Mlc-2a) suggested
that the generated iCMs were of an atrial subtype. As
early as 11 days after transduction, spontaneous contrac-
tions were observed and many colonies were beating by
day 15. The authors speculated that pluripotency repro-
gramming factors (especially Oct4) initially remove the
cell’s identity but epigenetic mechanisms, and soluble
factors in a staged protocol of differentiation media are
then capable of inducing the desired cell type. More
recently, this group demonstrated combining Oct4 [29]
with a small molecule cocktail consisting of SB431542
(ALK4/5/7 inhibitor), CHIR99021 (GSK3 inhibitor), par-
nate (LSD1/KDM1 inhibitor), and forskolin (adenylyl
cyclase activator) collectively known as SCPF [29], was
sufficient to wipe the fibroblast epigenetic memory, thus
enabling improved cell transdifferentiation with cardio-
myogenic signals (small molecules and growth factors). In
this case, BMP4 was added from day 6 after transduction
to induce a cardiomyocyte phenotype. The group ob-
served contracting clusters from day 20 and generated
99  17 beating foci on day 30 after 1  104 MEFs were
initially plated. Most of the derived cells indicated a
ventricular subtype with hardly any displaying atrial or
nodal features.
Chemically achieved transdifferentiation
Suppression of the starting cell epigenetic signature is
paramount to overcoming one major molecular roadblock
for successful transdifferentiation; namely the shutdown of
the fibroblast program, before an adoption of the desired
cell fate becomes possible. Cells not only undergo tran-
scriptional changes but also exhibit epigenetic changes in
DNA methylation and histone modifications [30,31], and it
are primarily these changes that convert the epigenetic
pattern of somatic cells to an embryonic stem cell-like state.
Several small molecules that block and inhibit enzymes
involved in epigenetic modifications, including histone
methylation or demethylation, can increase the efficiency
of transdifferentiation and can sometimes functionally
replace ectopic expression of certain transcription factors.
Routinely, G9a-mediated H3K9 methylation is necessary
for heterochromatinization and silencing of key pluripo-
tency genes, such as Oct4 and Rex1 during early embryo-
genesis [32]. DNA methyltransferase inhibitor, 5-
azacytidine, or histone deacetylase inhibitors (suberoyla-
nilide hydroxamic acid, trichostatin A and valproic acid)
improved reprogramming efficiency after transduction ofwww.sciencedirect.com the four iPSC transcription factors in MEFs [33]. A cell’s
epigenetic memory can be essentially erased by treating
established iPSCs with 5-azacytidine and trichostatin A
[33]. The use of small molecule compounds in cell trans-
differentiation, which could be better accepted for clinical
translation, has recently been highlighted with the com-
plete generation of iPSCs and neural progenitor cells via
small molecules [34–36]. More recently, transdifferentiat-
ing MEFs into cardiomyocytes (sometimes beating) using
chemically defined cocktails has been achieved with a
transition via a cardiac progenitor cell stage but not that
of a pluripotent stage [7]. Yet still, the induction efficien-
cies of iCMs using this, and other methods in vitro remain
disappointingly low.
In vivo efforts
Interestingly, in vivo approaches of direct cardiac repro-
gramming applied after experimental MI in mice obtain
higher efficiencies than in vitro approaches. Considering
that the fibrotic scar is primarily composed of ECM-
producing fibroblasts, this is indeed promising. Qian
et al. [37] and Song et al. [16] have both used genetic
lineage tracing to ascertain that in mouse infarcted hearts,
transdifferentiation of non-myocytes into functional
iCMs occurred. Both studies document improved func-
tional recovery and reduced fibrotic scar tissue. Since
then, other improvements to in vivo GMT transdiffer-
entiation have been made with respect to the delivery
vector [38,39] and preconditioning the myocardium with
angiogenic factors [40,41]. miR-based transdifferentiation
in vivo has also been reported by Jayawardena et al.
whereby their initial study determined that 1% of the
iCMs were of a fibroblast origin [6] and a more recent
study of the therapeutic effect of this treatment found
progressive improvement in cardiac function. These con-
version rates in vivo (1–35%) are encouraging; however, to
generate disease-in-a-dish models and in vitro iCM yields
suitable for transplantation, increased in vitro efficiencies
are required to achieve large-scale cultures.
The influence of ECM signalling
Many strategies have potential regarding transdifferentia-
tion to generate iCMs in vitro from somatic sources and
the direct reprogramming of resident cells in vivo
(Figure 1). The ECM serves as an important component
of all tissues, and its composition and mechanical proper-
ties play significant roles in the self-renewal or differen-
tiation of cells. ECM composition and signalling in stem
cell niches promotes the self-renewal of stem or progeni-
tor cells and this knowledge has been utilized early on in
embryonic stem cell culture for ESC maintenance in vitro
using MEFs secreting ECM [42], ECM-based substrates
such as Matrigel1 [43], specific ECM proteins such as
laminins, collagen type I, or vitronectin [44–46]. ECM
proteins have also been utilized to guide stem cell dif-
ferentiation to somatic cell types, including cardiomyo-
cytes [47–50]. For instance, collagen type IV has beenCurrent Opinion in Biotechnology 2016, 40:49–55
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Direct reprogramming of fibroblasts to a functional cardiomyocyte with or without a progenitor cell intermediate has been widely reported with
increasing efficiencies using transcription factors, miRs and small molecules. The evolution of these protocols will benefit greatly by the use of
cardio-stimulatory environments with biomaterials, extracellular matrices and dynamic cultures based on lessons learned in vivo, which could yield
significant efficiencies suitable for implantation. Additionally, using delivery vehicles of transdifferentiation factors that are based on biomaterial
and extracellular matrices, which are favourable towards cardiomyogenesis could further improve direct reprogramming in vivo.shown to increase the differentiation of mouse embryonic
stem cells into cardiac progenitor cells (CPCs) while
fibronectin can enhance CPC differentiation to cardio-
myocytes [51]. Additionally, to reprogram somatic cells at
least partially to multipotent cells, the use of embryonic
stem cell extracts [52] or animal oocyte extracts [53,54]
has been described. Zhang et al. induced multipotency in
fibroblasts by extracellular delivery of the ECM compo-
nent fibromodulin [55]. Interestingly, the multipotent
cells differentiated into derivatives of all three germ
layers including cardiomyocytes, skeletal myocytes, neu-
rons, pancreatic lineage cells, osteoblasts, and adipocytes
in vitro while omitting the risk of teratoma formation in
vivo [55]. More delivery approaches become available
when considering ECM-enhanced iCM generation as
the ECM can also serve as a depot for growth factors,
transcription factors and nucleic acid vectors (viruses and
plasmid constructs) for gene therapy [56]. However, oneCurrent Opinion in Biotechnology 2016, 40:49–55 such factor alone is not enough and therefore payloads
that can achieve sustained and programmed release of
many molecules at the same, or at staged time intervals
are paramount to the correct transdifferentiation of cells
in vivo [57,58].
Incorporation of biomechanical cues
Research focused on the interplay between physical and
developmental cues has demonstrated that mechanical
forces generated by cells or tissues are crucial for the
control of embryological development, morphogenesis
and tissue patterning [59]. The importance of the me-
chanical properties of a cell’s or tissue’s microenviron-
ment has been recognized by many in the field of tissue
engineering [51,60]. This has resulted in the design of
elaborate systems to mimic a native environment with
defined mechanical cues of surface rigidity, stretch and
strain. Some of these cues exist already in vivo, whichwww.sciencedirect.com
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tion is more successful in vivo. Ruan et al. have recently
shown that cyclic mechanical stress in 3D in vitro cultures
of ESC and hiPSC-derived CPCs favoured cardiac dif-
ferentiation and promoted cardiomyocyte structural and
functional maturation [61]. It is difficult to recapitulate
small molecule interventions in vivo, which suggests
other epigenetic occurrences present in the myocardium.
Again, such influences in vivo could be ECM signalling.
Recently it was shown that topography plays an instru-
mental role in the epigenetic state of the cell whereby the
study of Morez et al. cultured adult heart-derived progen-
itor cells on microgrooves (10 mm wide, 3 mm deep) to
enhance histone acetylation and cardiomyocyte differen-
tiation [62]. The growing range of functional biomater-
ials that can release drugs, proteins, growth factors and
ECM components, or that display an improved mechani-
cal functionality, is currently the focus of tissue engineer-
ing and regenerative medicine [63]. A temporally and
spatially controlled release of bioactive molecules from
such functional biomaterials can be achieved through the
combination of different mechanisms, like diffusion-
based release, biomaterial-degradation, or cell-triggered
release [64].
Conclusion
The generation of functional cardiac tissue in vitro by
transdifferentiating somatic cell sources can only be truly
realized and up-scaled by combining lessons learned from
cardiomyocyte derivation from iPSCs or stem cells,
whereby ECM biophysical cues and dynamic cultures
have yielded more mature iCMs with higher efficiencies.
This would enable the generation of patient-specific drug
testing systems and personalized engineering of cardiac
tissue in vitro.
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